{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T05:31:08Z","timestamp":1792992668985,"version":"4.5.0"},"reference-count":94,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T00:00:00Z","timestamp":1731024000000},"content-version":"vor","delay-in-days":99,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","ejinme.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.ejim.2024.04.011","type":"journal-article","created":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T01:43:33Z","timestamp":1713836613000},"page":"16-25","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Single-pill combination for treatment of hypertension: Just a matter of practicality or is there a real clinical benefit?"],"prefix":"10.1016","volume":"126","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6968-3266","authenticated-orcid":false,"given":"A","family":"Coca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5914-0735","authenticated-orcid":false,"given":"SP","family":"Whelton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Camafort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8865-0929","authenticated-orcid":false,"given":"JP","family":"L\u00f3pez-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3945-7529","authenticated-orcid":false,"given":"E","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"25","key":"10.1016\/j.ejim.2024.04.011_bib0001","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","article-title":"GBD-NHLBI-JACC Global Burden of Cardiovascular Diseases Writing Group. Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study","volume":"76","author":"Roth","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"25","key":"10.1016\/j.ejim.2024.04.011_bib0002","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1016\/j.jacc.2023.11.007","article-title":"on behalf of the Global Burden of Cardiovascular Diseases and Risks Collaborators. Global burden of cardiovascular diseases and risks, 1990-2022","volume":"82","author":"Mensah","year":"2023","journal-title":"J Am Col Cardiol"},{"issue":"11","key":"10.1016\/j.ejim.2024.04.011_bib0003","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1001\/jama.2023.2307","article-title":"Cardiovascular risk factor prevalence, treatment, and control in US Adults Aged 20 to 44 years, 2009 to March 2020","volume":"329","author":"Aggarwal","year":"2023","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.ejim.2024.04.011_bib0004","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1001\/jamacardio.2023.3241","article-title":"Prevalence and overlap of cardiac, renal, and metabolic conditions in US Adults, 1999-2020","volume":"8","author":"Ostrominski","year":"2023","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ejim.2024.04.011_bib0005","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1111\/jch.13922","article-title":"The slowdown in the reduction rate of premature mortality from cardiovascular diseases puts the Americas at risk of achieving SDG 3.4: a population trend analysis of 37 countries from 1990 to 2017","volume":"22","author":"Martinez","year":"2020","journal-title":"J Clin Hypertens"},{"key":"10.1016\/j.ejim.2024.04.011_bib0006","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1093\/eurheartj\/ehab892","article-title":"European Society of Cardiology. European Society of Cardiology: cardiovascular disease statistics 2021","volume":"43","author":"Timmis","year":"2022","journal-title":"Eur Heart J"},{"issue":"30","key":"10.1016\/j.ejim.2024.04.011_bib0007","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1093\/eurheartj\/ehac113","article-title":"Risk factors, cardiovascular disease, and mortality in South America: a PURE substudy","volume":"43","author":"Lopez-Jaramillo","year":"2022","journal-title":"Eur Heart J"},{"issue":"14","key":"10.1016\/j.ejim.2024.04.011_bib0008","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa2206916","article-title":"The Global Cardiovascular Risk Consortium. Global effect of modifiable risk factors on cardiovascular disease and mortality","volume":"389","year":"2023","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ejim.2024.04.011_bib0009","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/jch.13426","article-title":"Fixed-dose combination pharmacologic therapy to improve hypertension control worldwide: clinical perspective and policy implications","volume":"21","author":"DiPette","year":"2019","journal-title":"J Clin Hypertens"},{"key":"10.1016\/j.ejim.2024.04.011_bib0010","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/joim.13678","article-title":"Perspectives on improving blood pressure control to reduce the clinical and economic burden of hypertension","volume":"294","author":"Mancia","year":"2023","journal-title":"J Intern Med"},{"issue":"6","key":"10.1016\/j.ejim.2024.04.011_bib0011","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1161\/HYP.0000000000000066","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2024.04.011_bib0012","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1097\/HJH.0000000000001940","article-title":"2018 ESC\/ESH guidelines for the management of arterial hypertension. The task force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH)","volume":"36","author":"Williams","year":"2018","journal-title":"J Hypertens"},{"key":"10.1016\/j.ejim.2024.04.011_bib0013","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1097\/HJH.0000000000002453","article-title":"2020 International Society of Hypertension global hypertension practice guidelines","volume":"38","author":"Unger","year":"2020","journal-title":"J Hypertens"},{"issue":"1","key":"10.1016\/j.ejim.2024.04.011_bib0014","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1161\/HYPERTENSIONAHA.121.18192","article-title":"Hypertension pharmacological treatment in adults: a World Health Organization guideline executive summary","volume":"79","author":"Al-Makki","year":"2022","journal-title":"Hypertension"},{"issue":"12","key":"10.1016\/j.ejim.2024.04.011_bib0015","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","volume":"41","author":"Mancia","year":"2023","journal-title":"J Hypertens"},{"issue":"10414","key":"10.1016\/j.ejim.2024.04.011_bib0016","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1016\/S0140-6736(23)01733-6","article-title":"\u03b2 blockers switched to first-line therapy in hypertension","volume":"402","author":"Messerli","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2024.04.011_bib0017","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.amjmed.2008.09.038","article-title":"Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 Trials","volume":"122","author":"Wald","year":"2009","journal-title":"Am J Med"},{"issue":"11","key":"10.1016\/j.ejim.2024.04.011_bib0018","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1097\/HJH.0b013e32833e1150","article-title":"Evaluating 24-h antihypertensive efficacy by the smoothness index: a meta-analysis of an ambulatory blood pressure monitoring database","volume":"28","author":"Parati","year":"2010","journal-title":"J Hypertens"},{"issue":"4","key":"10.1016\/j.ejim.2024.04.011_bib0019","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1097\/HJH.0000000000001608","article-title":"Effect of antihypertensive treatment on 24-h blood pressure variability: pooled individual data analysis of ambulatory blood pressure monitoring studies based on olmesartan mono or combination treatment","volume":"36","author":"Omboni","year":"2018","journal-title":"J Hypertens"},{"issue":"6","key":"10.1016\/j.ejim.2024.04.011_bib0020","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1097\/00005344-200206000-00007","article-title":"Trough-to-peak ratio, smoothness index, and circadian blood pressure profile after treatment with once-daily fixed combination of losartan 100 and hydrochlorothiazide 25 in essential hypertension","volume":"39","author":"Coca","year":"2002","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.ejim.2024.04.011_bib0021","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1161\/HYPERTENSIONAHA.108.123455","article-title":"Simplified approach to the treatment of uncomplicated hypertension. A cluster randomized, controlled trial","volume":"53","author":"Feldman","year":"2009","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2024.04.011_bib0022","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0828-282X(07)70798-5","article-title":"The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy","volume":"23","author":"Khan","year":"2007","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.ejim.2024.04.011_bib0023","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1001\/jama.2018.10359","article-title":"Fixed low-dose triple combination antihypertensive medication vs usual care for blood pressure control in patients with mild to moderate hypertension in Sri Lanka: a randomized clinical trial","volume":"320","author":"Webster","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.ejim.2024.04.011_bib0024","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/S0140-6736(21)01922-X","article-title":"Initial treatment with a single pill containing quadruple combination of quarter doses of blood pressure medicines versus standard dose monotherapy in patients with hypertension (QUARTET): a phase 3, randomised, double-blind, active-controlled trial","volume":"398","author":"Chow","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2024.04.011_bib0025","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1161\/HYPERTENSIONAHA.112.194167","article-title":"Initial monotherapy and combination therapy and hypertension control the first year","volume":"59","author":"Egan","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2024.04.011_bib0026","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1111\/jch.13413","article-title":"Clinical outcomes in hypertensive patients treated with a single-pill fixed-dose combination of renin-angiotensin system inhibitor and thiazide diuretic","volume":"20","author":"Ho","year":"2018","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.ejim.2024.04.011_bib0027","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/j.jacc.2019.08.014","article-title":"Therapeutic inertia in cardiovascular disease prevention time to move the bar","volume":"74","author":"Dixon","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2024.04.011_bib0028","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1161\/HYPERTENSIONAHA.118.11308","article-title":"Initial antihypertensive treatment strategies and therapeutic inertia: evidence from a large population-based cohort","volume":"72","author":"Rea","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2024.04.011_bib0029","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A randomized trial of intensive versus standard blood-pressure control","volume":"373","author":"Wright","year":"2015","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ejim.2024.04.011_bib0030","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1161\/HYPERTENSIONAHA.121.17233","article-title":"Blood pressure intervention and control in SPRINT","volume":"79","author":"Cushman","year":"2022","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2024.04.011_bib0031","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1136\/bmj.326.7404.1427","article-title":"Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials","volume":"326","author":"Law","year":"2003","journal-title":"Bmj-Brit Med J"},{"key":"10.1016\/j.ejim.2024.04.011_bib0032","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1161\/CIRCULATIONAHA.123.064964","article-title":"Effect of initial treatment with a single pill containing quadruple combination of quarter doses of blood pressure medicines versus standard dose monotherapy in patients with hypertension on ambulatory blood pressure indices: results from the QUARTET study","volume":"148","author":"Nolde","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2024.04.011_bib0033","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.clinthera.2007.01.007","article-title":"Comparison of valsartan\/hydrochlorothiazide combination therapy at doses up to 320\/25 mg versus monotherapy: a double-blind, placebo-controlled study followed by long-term combination therapy in hypertensive adults","volume":"29","author":"Pool","year":"2007","journal-title":"Clin Ther"},{"key":"10.1016\/j.ejim.2024.04.011_bib0034","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1001\/archinte.1989.00390120043009","article-title":"Potassium restoration in hypertensive patients made hypokalemic by hydrochlorothiazide","volume":"149","author":"Schnaper","year":"1989","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ejim.2024.04.011_bib0035","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S0895-7061(01)02178-1","article-title":"Vasodilatory edema: a common side effect of antihypertensive therapy","volume":"14","author":"Messerli","year":"2001","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.ejim.2024.04.011_bib0036","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1161\/01.HYP.35.2.621","article-title":"Amlodipine, enalapril, and dependent leg edema in essential hypertension","volume":"35","author":"Pedrinelli","year":"2000","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2024.04.011_bib0037","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.amjmed.2010.08.007","article-title":"Effect of Renin-Angiotensin system blockade on calcium channel blocker-associated peripheral edema","volume":"124","author":"Makani","year":"2011","journal-title":"Am J Med"},{"key":"10.1016\/j.ejim.2024.04.011_bib0038","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.18425","article-title":"Magnitude of and characteristics associated with the treatment of calcium channel blocker-induced lower-extremity edema with loop diuretics","volume":"2","author":"Vouri","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ejim.2024.04.011_bib0039","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1001\/jama.2016.7050","article-title":"Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged >\/=75 years: a randomized clinical trial","volume":"315","author":"Williamson","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.ejim.2024.04.011_bib0040","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/HJH.0000000000002294","article-title":"Medication adherence in hypertension","volume":"38","author":"Poulter","year":"2020","journal-title":"J Hypertens"},{"key":"10.1016\/j.ejim.2024.04.011_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjmed.2011.12.013","article-title":"Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients","volume":"125","author":"Naderi","year":"2012","journal-title":"Am J Med"},{"issue":"8","key":"10.1016\/j.ejim.2024.04.011_bib0042","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1177\/2047487318825350","article-title":"Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry","volume":"26","author":"Kotseva","year":"2019","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.ejim.2024.04.011_bib0043","doi-asserted-by":"crossref","first-page":"n1493","DOI":"10.1136\/bmj.n1493","article-title":"Medication adherence in cardiovascular medicine","volume":"374","author":"Simon","year":"2021","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.ejim.2024.04.011_bib0044","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s40256-021-00505-6","article-title":"Improving the management of hypertension by tackling awareness, adherence, and clinical inertia: a symposium report","volume":"22","author":"Pathak","year":"2022","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.ejim.2024.04.011_bib0045","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1093\/eurheartj\/eht295","article-title":"Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences","volume":"34","author":"Chowdhury","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2024.04.011_bib0046","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1097\/HJH.0b013e328342ca97","article-title":"Better compliance to antihypertensive medications reduces cardiovascular risk","volume":"29","author":"Corrao","year":"2011","journal-title":"J Hypertens"},{"key":"10.1016\/j.ejim.2024.04.011_bib0047","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1161\/HYPERTENSIONAHA.120.14683","article-title":"Antihypertensive treatment in elderly frail patients. evidence from a large italian database","volume":"76","author":"Rea","year":"2020","journal-title":"Hypertension"},{"issue":"5","key":"10.1016\/j.ejim.2024.04.011_bib0048","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1080\/08037051.2021.1963209","volume":"30","author":"Burnier","year":"2021","journal-title":"Blood Press"},{"issue":"1","key":"10.1016\/j.ejim.2024.04.011_bib0049","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/HYP.0000000000000203","article-title":"American Heart Association Council on Hypertension; Council on Cardiovascular and Stroke Nursing; and Council on Clinical Cardiology. Medication adherence and blood pressure control: a scientific statement from the American Heart Association","volume":"79","author":"Choudhry","year":"2022","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2024.04.011_bib0050","article-title":"Guidelines should consider clinicians\u2019 time needed to treat","volume":"380","author":"Johansson","year":"2023","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.ejim.2024.04.011_bib0051","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1161\/HYPERTENSIONAHA.116.08729","article-title":"Risk factors for nonadherence to antihypertensive treatment","volume":"69","author":"Gupta","year":"2017","journal-title":"Hypertension"},{"issue":"6","key":"10.1016\/j.ejim.2024.04.011_bib0052","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1097\/HJH.0000000000002398","article-title":"Nonadherence to antihypertensive medications is related to pill burden in apparent treatment-resistant hypertensive individuals","volume":"38","author":"Lawson","year":"2020","journal-title":"J Hypertens"},{"issue":"3","key":"10.1016\/j.ejim.2024.04.011_bib0053","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1161\/HYPERTENSIONAHA.121.17514","article-title":"Fadl Elmula FEM. Detection of nonadherence to antihypertensive treatment by measurements of serum drug concentrations","volume":"78","author":"Bergland","year":"2021","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2024.04.011_bib0054","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1161\/HYPERTENSIONAHA.120.15781","article-title":"Adherence to single-pill versus free-equivalent combination therapy in hypertension. A systematic review and meta-analysis","volume":"77","author":"Parati","year":"2021","journal-title":"Hypertension"},{"issue":"6","key":"10.1016\/j.ejim.2024.04.011_bib0055","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1097\/HJH.0000000000002381","article-title":"Impact of single-pill combination therapy on adherence, blood pressure control, and clinical outcomes: a rapid evidence assessment of recent literature","volume":"38","author":"Tsioufis","year":"2020","journal-title":"J Hypertens"},{"issue":"5","key":"10.1016\/j.ejim.2024.04.011_bib0056","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.14211","article-title":"Cost-related medication nonadherence and desire for medication cost information among adults aged 65 years and older in the US in 2022","volume":"6","author":"Dusetzina","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ejim.2024.04.011_bib0057","first-page":"459","article-title":"Effects of blood pressure unawareness and poor adherence to antihypertensive drugs on outcomes of cerebrovascular accidents among patients with their first-ever stroke","volume":"41","author":"Bawand","year":"2023","journal-title":"J Hypertens"},{"issue":"17","key":"10.1016\/j.ejim.2024.04.011_bib0058","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1161\/CIRCULATIONAHA.112.096156","article-title":"Trends in antihypertensive medication use and blood pressure control among United States adults with hypertension: the National Health And Nutrition Examination Survey, 2001 to 2010","volume":"126","author":"Gu","year":"2012","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.ejim.2024.04.011_bib0059","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/jhh.2010.64","article-title":"How early should blood pressure control be achieved for optimal cardiovascular outcomes","volume":"25","author":"Weir","year":"2011","journal-title":"J Hum Hypertens"},{"issue":"9426","key":"10.1016\/j.ejim.2024.04.011_bib0060","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1016\/S0140-6736(04)16451-9","article-title":"Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial","volume":"363","author":"Julius","year":"2004","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.ejim.2024.04.011_bib0061","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","article-title":"Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)","volume":"288","author":"Furberg","year":"2002","journal-title":"JAMA"},{"issue":"9489","key":"10.1016\/j.ejim.2024.04.011_bib0062","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(05)67185-1","volume":"366","author":"Dahl\u00f6f","year":"2005","journal-title":"The Lancet"},{"issue":"1","key":"10.1016\/j.ejim.2024.04.011_bib0063","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/08037050510008823","article-title":"The study on cognition and prognosis in the elderly (SCOPE) \u2013 major CV events and stroke in subgroups of patients","volume":"14","author":"Trenkwalder","year":"2005","journal-title":"Blood Press"},{"issue":"12","key":"10.1016\/j.ejim.2024.04.011_bib0064","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1097\/HJH.0000000000000378","article-title":"Effects of blood pressure lowering on outcome incidence in hypertension.1. Overview, meta-analyses, and meta-regression analyses of randomized trials","volume":"32","author":"Thomopoulos","year":"2014","journal-title":"J Hypertens"},{"key":"10.1016\/j.ejim.2024.04.011_bib0065","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.ijcard.2017.12.026","article-title":"Is early and fast blood pressure control important in hypertension management?","volume":"254","author":"Volpe","year":"2018","journal-title":"Int J Cardiol"},{"issue":"9","key":"10.1016\/j.ejim.2024.04.011_bib0066","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/jch.12164","article-title":"Determinants of achieving early blood pressure control with monotherapy in a primary care setting","volume":"15","author":"Stewart","year":"2013","journal-title":"J Clin Hypertens"},{"issue":"2","key":"10.1016\/j.ejim.2024.04.011_bib0067","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1080\/08037050701395571","article-title":"Exceptional early blood pressure control rates: the ACCOMPLISH trial","volume":"16","author":"Jamerson","year":"2007","journal-title":"Blood Press"},{"issue":"5","key":"10.1016\/j.ejim.2024.04.011_bib0068","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/jch.14656","article-title":"Comparison of efficacy and safety between third-dose triple and third-dose dual antihypertensive combination therapies in patients with hypertension","volume":"25","author":"Sung","year":"2023","journal-title":"J Clin Hypertens"},{"issue":"3","key":"10.1016\/j.ejim.2024.04.011_bib0069","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1097\/HJH.0b013e328342ef04","article-title":"Blood pressure control by the nifedipine GITS-telmisartan combination in patients at high cardiovascular risk: the TALENT study","volume":"29","author":"Mancia","year":"2011","journal-title":"J Hypertens"},{"issue":"6","key":"10.1016\/j.ejim.2024.04.011_bib0070","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/1755-5922.12003","article-title":"Improved blood pressure control with nifedipine GITS\/valsartan combination versus high-dose valsartan monotherapy in mild-to-moderate hypertensive patients from asia: results from the ADVISE study, a randomized trial","volume":"30","author":"Ke","year":"2012","journal-title":"Cardiovasc Ther"},{"issue":"6","key":"10.1016\/j.ejim.2024.04.011_bib0071","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1001\/jamacardio.2022.0471","article-title":"Association of low-dose triple combination therapy vs usual care with time at target blood pressure: a secondary analysis of the TRIUMPH randomized clinical trial","volume":"7","author":"Gnanenthiran","year":"2022","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ejim.2024.04.011_bib0072","series-title":"World Health Organization-Wellcome Trust meeting report, 1-3 August","article-title":"Secondary preven- tion of noncommunicable diseases in low-and middle-income countries through community-based and health service interventions","year":"2001"},{"issue":"7404","key":"10.1016\/j.ejim.2024.04.011_bib0073","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1136\/bmj.326.7404.1419","article-title":"A strategy to reduce cardiovascular disease by more than 80 %","volume":"326","author":"Wald","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.ejim.2024.04.011_bib0074","unstructured":"World Heart Federation. The polypill could avoid millions of premature deaths, heart attacks and strokes every year, say leading cardiology experts; 2021. Available from: https:\/\/world-heart-federation.org\/news\/the-polypill-could-avoid-millions-of-premature-deaths-heart-attacks-and-strokes- every-year-say-leading-cardiology-experts. Accessed November 17, 2023."},{"issue":"1","key":"10.1016\/j.ejim.2024.04.011_bib0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0210988","article-title":"Effect of evidence-based therapy for secondary prevention of cardiovascular disease: systematic review and meta-analysis","volume":"14","author":"Ma","year":"2019","journal-title":"PLoS ONE"},{"issue":"3","key":"10.1016\/j.ejim.2024.04.011_bib0076","doi-asserted-by":"crossref","first-page":"e292","DOI":"10.1016\/S2214-109X(18)30031-7","article-title":"Inequalities in the use of secondary prevention of cardiovascular disease by socioeconomic status: evidence from the PURE observational study","volume":"6","author":"Murphy","year":"2018","journal-title":"Lancet Glob Health"},{"issue":"4","key":"10.1016\/j.ejim.2024.04.011_bib0077","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.gheart.2016.06.001","article-title":"Secondary CV prevention in South America in a community setting: the PURE study","volume":"12","author":"Avezum","year":"2017","journal-title":"Glob Heart"},{"issue":"10","key":"10.1016\/j.ejim.2024.04.011_bib0078","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s11886-021-01568-2","volume":"23","author":"McEvoy","year":"2021","journal-title":"Curr Cardiol Rep"},{"issue":"11","key":"10.1016\/j.ejim.2024.04.011_bib0079","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2020-002640","article-title":"Availability and affordability of medicines and cardiovascular outcomes in 21 high-income, middle-income and low-income countries","volume":"5","author":"Chow","year":"2020","journal-title":"BMJ Glob Health"},{"issue":"Suppl 8","key":"10.1016\/j.ejim.2024.04.011_bib0080","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12919-023-00268-9","article-title":"Multinational Discussion G. The use of the CNIC-Polypill in real-life clinical practice: opportunities and challenges in patients at very high risk of atherosclerotic cardiovascular disease - expert panel meeting report","volume":"17","author":"Grigorian-Shamagian","year":"2023","journal-title":"BMC Proc"},{"issue":"9672","key":"10.1016\/j.ejim.2024.04.011_bib0081","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(09)60611-5","article-title":"Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial","volume":"373","author":"Indian Polycap","year":"2009","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ejim.2024.04.011_bib0082","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1161\/CIRCOUTCOMES.111.963637","article-title":"Comparison of risk factor reduction and tolerability of a full-dose polypill (with potassium) versus low-dose polypill (polycap) in individuals at high risk of cardiovascular diseases: the Second Indian Polycap Study (TIPS-2) investigators","volume":"5","author":"Yusuf","year":"2012","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"3","key":"10.1016\/j.ejim.2024.04.011_bib0083","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1056\/NEJMoa2028220","article-title":"Polypill with or without aspirin in persons without cardiovascular disease","volume":"384","author":"Yusuf","year":"2021","journal-title":"N Engl J Med"},{"issue":"10199","key":"10.1016\/j.ejim.2024.04.011_bib0084","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S0140-6736(19)31791-X","article-title":"Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial","volume":"394","author":"Roshandel","year":"2019","journal-title":"Lancet"},{"issue":"10306","key":"10.1016\/j.ejim.2024.04.011_bib0085","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S0140-6736(21)01827-4","article-title":"Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis","volume":"398","author":"Joseph","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2024.04.011_bib0086","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ijcard.2022.05.015","article-title":"The CNIC-Polypill reduces recurrent major cardiovascular events in real-life secondary prevention patients in Spain: the NEPTUNO study","volume":"361","author":"Gonzalez-Juanatey","year":"2022","journal-title":"Int J Cardiol"},{"issue":"11","key":"10.1016\/j.ejim.2024.04.011_bib0087","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1056\/NEJMoa2208275","article-title":"Polypill strategy in secondary cardiovascular prevention","volume":"387","author":"Castellano","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2024.04.011_bib0088","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.pcad.2022.01.005","article-title":"Association of polypill therapy with cardiovascular outcomes, mortality, and adherence: a systematic review and meta-analysis of randomized controlled trials","volume":"73","author":"Rao","year":"2022","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.ejim.2024.04.011_bib0089","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1097\/HJH.0000000000002464","article-title":"A practical approach to switch from a multiple pill therapeutic strategy to a polypill-based strategy for cardiovascular prevention in patients with hypertension","volume":"38","author":"Coca","year":"2020","journal-title":"J Hypertens"},{"issue":"3","key":"10.1016\/j.ejim.2024.04.011_bib0090","article-title":"Polypill in cardiovascular disease prevention: recent advances","volume":"133","author":"Coca","year":"2023","journal-title":"Pol Arch Intern Med"},{"key":"10.1016\/j.ejim.2024.04.011_bib0091","doi-asserted-by":"crossref","first-page":"605","DOI":"10.2147\/VHRM.S421024","article-title":"Benefits of the polypill on medication adherence in the primary and secondary prevention of cardiovascular disease: a systematic review","volume":"19","author":"Lopez-Lopez","year":"2023","journal-title":"Vasc Health Risk Manag"},{"issue":"13","key":"10.1016\/j.ejim.2024.04.011_bib0092","doi-asserted-by":"crossref","first-page":"975","DOI":"10.2217\/cer-2021-0105","article-title":"Evaluating patients' satisfaction and preferences with a secondary prevention cardiovascular polypill: the Aurora Study","volume":"10","author":"Cosin-Sales","year":"2021","journal-title":"J Comp Eff Res"},{"key":"10.1016\/j.ejim.2024.04.011_bib0093","doi-asserted-by":"crossref","first-page":"g3318","DOI":"10.1136\/bmj.g3318","article-title":"Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care","volume":"348","author":"Selak","year":"2014","journal-title":"BMJ"},{"issue":"38","key":"10.1016\/j.ejim.2024.04.011_bib0094","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620524001729?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620524001729?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T07:07:59Z","timestamp":1731049679000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620524001729"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":94,"alternative-id":["S0953620524001729"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2024.04.011","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Single-pill combination for treatment of hypertension: Just a matter of practicality or is there a real clinical benefit?","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2024.04.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V. on behalf of European Federation of Internal Medicine.","name":"copyright","label":"Copyright"}]}}